Osteopontin (Opn) is a phosphorylated glycoprotein, identified as an adhesive and migratory substrate for several cell types, which is highly expressed by osteoblasts within the hemopoietic stem cell (HSC) niche. We have previously demonstrated an unrecognised critical role for Opn in the regulation of the physical location and proliferation of HSC. Within the bone marrow the presence of Opn is restricted to the endosteal bone surface and we now have evidence that within this region, Opn exists in both the native as well as a cleaved form. In addition, we have shown that the cleaved form acts as a physiological negative regulator of HSC proliferation and differentiation through binding to both α4β1 and α9β1 integrins. We recently demonstrated for the first time the expression of α9β1 on human HSC, with an inverse correlation between the expression of α9β1 and CD38, demonstrating that this integrin is more abundantly expressed on more primitive HSC. In contrast α4β1 expression mirrors that of CD38 and is expressed at higher levels on committed progenitors. Similarly, murine HSC also express α9β1, with endosteal HSC exhibiting a higher level of expression compared to HSC from other bone marrow regions. Furthermore, we now have direct evidence of endogenous binding of Opn to both α4β1 and α9β1 on human cord blood HSC through coimmunoprecipitation experiments utilizing antibodies specific for α4 and α9β1. In vitro, these cells specifically bind to OPN via both α4 and α9β1. We have now explored the signalling pathways invoked following the interaction between OPN and these individual integrins expressed on HSC. Previous studies in other cellular systems have demonstrated that binding of ligands to α9 specifically signals via either SSAT or paxillin to result in de-adhesion or augmented cell migration respectively. We have recently made the novel observation that human cord blood CD34+ cells and murine endosteal HSC and central HSC cells express SSAT and paxillin. Thus despite the high degree of homology exhibited by the α4 and α9 cytoplasmic domains, binding of each integrin by one ligand can give rise to specific functional responses, attributed to the association of distinct adapter and signalling proteins. These data provide strong evidence that Opn is an important component of the HSC niche, participating in the attraction and retention of HSC to this region, where it acts as a negative regulator of HSC proliferation and differentiation via binding to one of two integrins and invoking specific signalling.
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